VEGF165-transfected autologous CD34+ cells

VEGF165-transfected autologous CD34+ cells is an experimental gene-modified cell therapy being developed by Qingdao University for the treatment of atherosclerotic lower limb ischemia, including conditions such as arteriosclerosis obliterans and diabetic foot. The therapy involves the isolation of CD34+ hematopoietic stem cells from the patient's own peripheral blood, which are then genetically modified via transfection with the vascular endothelial growth factor 165 (VEGF165) gene. These modified cells are administered through intramuscular transplantation into the ischemic limb. Once transplanted, the cells express VEGF165, a potent pro-angiogenic factor that stimulates the formation of new blood vessels (angiogenesis), thereby improving perfusion and oxygenation in the ischemic tissue. This approach aims to provide a therapeutic option for elderly patients with severe peripheral arterial disease who may have limited surgical or endovascular options.

Other names

Autologous CD34+ cells transfected with VEGF165 genePeripheral blood autologous CD34+ cell transplantation